Basecamp Research Raises $140 Million for AI Designed Therapeutics
Sep 24, 2026
Funding
Pathos AI Raises $237 Million at $3 Billion Valuation
Oct 23, 2026
Pathos AI raised $237 million in a Series E round led by Bristol Myers Squibb. The company will expand its Foundry AI platform and advance four oncology drug candidates.
Pathos AI raised $237 million in a Series E round led by Bristol Myers Squibb, the company announced in a press release. The financing values the clinical stage oncology company at about $3 billion after the investment.
Pathos AI will use the capital to expand Foundry, its AI platform for drug development, and advance four clinical assets. The platform uses thousands of specialized AI agents to combine clinical, genomic and biological specimen data with information about competing drug programs.
The company will prioritize JSKN016, a TROP2 and HER3 bispecific antibody drug conjugate, as it moves toward registrational studies. Funding will also support pocenbrodib, AZD4241 and the MET kinase inhibitor DO-2.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Funding
Oct 23 Cuttable Raises A$20 Million and Expands AI Ad Platform Oct 23 Kevel Raises $52 Million for Retail Media Platform Oct 23 Cygrid Raises €2.66 Million for AI Agent Access Controls Oct 23 Nvidia and TCV Invest in Higgsfield Series B Extension Oct 23 Cognitive Credit Raises $40 Million for Credit Analysis ToolsMore from Life Sciences
Oct 23 BioVid launches synthetic physician research platform Oct 23 NICE Recommends Five AI Tools for Prostate MRI Scans Oct 23 Boehringer Ingelheim and Microsoft to Study Digital Patient Twins Oct 23 Coreline Soft Receives FDA Clearance for Aortic CT Analysis Software Oct 23 Ping An Good Doctor Profit Rises 35% as AI Doctor Users Near 13 MillionFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
The Hackett Group
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Enveda Raises $311 Million for AI Drug Discovery
Sep 24, 2026
Funding
Pigment raises $250 million at $2.3 billion valuation
Oct 21, 2026
Funding
Sensydia Raises More Than $6 Million for AI Cardiac System
Oct 13, 2026
Funding
Positron AI Raises $875 Million at $5 Billion Valuation
Oct 19, 2026
Chips
PaleBlueDot AI Raises $200 Million at $3.2 Billion Valuation
Oct 02, 2026
Data Centers
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.